Department of Hepatological Surgery, Maoming People's Hospital, Maoming 525000, China.
Department of Pharmacy, Gaozhou People's Hospital, Gaozhou 525200, China.
Aging (Albany NY). 2021 Aug 30;13(16):20698-20715. doi: 10.18632/aging.203456.
There is increasing evidence of the epigenetic regulation of the immune response in cancer. However, the specific functions and mechanisms of RNA N6-methyladenosine (m6A) modification in the cell infiltration in the hepatocellular carcinoma (HCC) tumor microenvironment (TME) is unknown.
We systematically analyzed the m6A-modification patterns of 371 HCC samples based on 23 m6A regulators, and determined their correlation with TME cell-infiltrating characteristics. Principal-component analysis algorithms was used to calculate the m6Ascore and clarify the m6A-modification patterns of individual tumors.
Three different m6A-modification patterns were identified in HCC, wherein the m6Acluster B and m6Acluster A had the best and worst prognosis, respectively. These three patterns had different TME cell infiltration characteristics and biological behavior. An m6A-scoring signature was constructed to evaluate the m6A-modification patterns within individual tumors. A low m6Ascore was associated with a low overall survival and high clinical stage. Moreover, the m6A-scoring signature was characterized by distinct immunotherapeutic landscapes; a high m6A score indicated a higher immune checkpoint inhibitor score in the anti-PD-1 treatment alone, anti-CTLA-4 treatment alone, or combined anti-CTLA-4/PD-1 treatment cohorts, which reflected significant treatment and clinical benefits.
Our study highlights the significant role of the m6A modification in the HCC TME. A scoring signature to clarify the individual m6A-modification pattern would help us understand the HCC TME infiltration characterization and, thus, would guide the selection of more effective immunotherapeutic strategies.
越来越多的证据表明,表观遗传调控参与了癌症的免疫反应。然而,RNA N6-甲基腺苷(m6A)修饰在肝癌(HCC)肿瘤微环境(TME)中细胞浸润的具体功能和机制尚不清楚。
我们系统分析了基于 23 个 m6A 调节剂的 371 个 HCC 样本的 m6A 修饰模式,并确定了它们与 TME 细胞浸润特征的相关性。采用主成分分析算法计算 m6A 评分,阐明单个肿瘤的 m6A 修饰模式。
在 HCC 中鉴定出三种不同的 m6A 修饰模式,其中 m6Acluster B 和 m6Acluster A 具有最佳和最差的预后。这三种模式具有不同的 TME 细胞浸润特征和生物学行为。构建了 m6A 评分特征来评估单个肿瘤内的 m6A 修饰模式。低 m6A 评分与总生存期较短和临床分期较高相关。此外,m6A 评分特征具有独特的免疫治疗景观;高 m6A 评分表明在单独抗 PD-1 治疗、单独抗 CTLA-4 治疗或联合抗 CTLA-4/PD-1 治疗队列中免疫检查点抑制剂评分较高,这反映了显著的治疗和临床获益。
本研究强调了 m6A 修饰在 HCC TME 中的重要作用。评分特征可明确个体 m6A 修饰模式,有助于我们了解 HCC TME 浸润特征,从而指导选择更有效的免疫治疗策略。